Core Viewpoint - The article emphasizes the urgent need for weight management due to the global obesity crisis, which is linked to various metabolic diseases and health issues. It advocates for a dual approach to weight management: self-discipline through lifestyle changes and external interventions such as medication or surgery [6][10]. Summary by Sections Obesity as a Public Health Crisis - The National Health Commission has issued a warning about the critical state of public health due to obesity, which is a major contributor to diseases like type 2 diabetes and cardiovascular issues. The article highlights real-life examples of individuals facing health problems due to excessive weight, reinforcing the need for immediate action [6]. Current Weight Management Approaches - Weight management strategies include self-discipline through exercise, regular sleep, and scientific dietary practices, alongside pharmacological interventions like GLP-1 receptor agonists such as semaglutide and liraglutide, which have been approved for weight loss [7][10]. New Developments in Obesity Treatment - Recent research from Stanford University has identified a new natural bioactive peptide, BRINP2-related peptide (BRP), which shows significant potential in reducing food intake and improving blood sugar levels in animal models. This peptide operates independently of known appetite-related hormones, suggesting a novel mechanism for obesity treatment [8][14]. Mechanism of Action of BRP - BRP has been shown to activate specific neuronal pathways in the hypothalamus, influencing appetite regulation without causing anxiety or behavioral changes. The peptide's effects were observed in both mice and mini-pigs, demonstrating its ability to suppress food intake effectively [14][16]. Experimental Results - In mouse studies, BRP significantly reduced food intake and body weight, with a dosage of 5 mg/kg leading to an average weight loss of 4 grams over 14 days. The peptide also improved glucose tolerance and insulin sensitivity, comparable to the effects of liraglutide [14][16]. Future Directions - The discovery of BRP opens new avenues for obesity research and treatment strategies. However, further studies are needed to explore its detailed mechanisms and long-term safety before clinical applications can be realized [18].

Core Viewpoint - The article emphasizes the urgent need for weight management due to the global obesity crisis, which is linked to various metabolic diseases and health issues. It advocates for a dual approach to weight management: self-discipline through lifestyle changes and external interventions such as medication or surgery [6][10]. Summary by Sections Obesity as a Public Health Crisis - The National Health Commission has issued a warning about the critical state of public health due to obesity, which is a major contributor to diseases like type 2 diabetes and cardiovascular issues [6]. Weight Management Approaches - Effective weight management requires both self-discipline (through exercise, diet, and sleep) and external aids (such as medications and surgical options) [6]. GLP-1 Receptor Agonists - Medications like Semaglutide and Liraglutide, which are GLP-1 receptor agonists, have been approved for weight loss. These drugs mimic the natural peptide GLP-1 in the body, aiding in appetite control and energy balance [7]. Discovery of BRINP2-Related Peptide (BRP) - A new peptide, BRP, has been identified by a Stanford University team using AI tools. This peptide shows significant potential in reducing food intake and improving blood sugar levels, comparable to GLP-1 receptor agonists, without causing anxiety or behavioral changes [8][14]. Mechanism of Action - BRP operates independently from known appetite-related peptides and activates specific neuronal pathways in the hypothalamus to regulate appetite. It enhances fat oxidation and reduces overall food intake without adverse effects [14][16]. Experimental Results - In mouse studies, BRP significantly reduced food intake and body weight, improving glucose tolerance and insulin sensitivity. The effects were similar to those of Liraglutide, indicating its potential as a weight loss treatment [14][16]. Future Directions - The discovery of BRP opens new avenues for obesity treatment, although further research is needed to understand its mechanisms and long-term safety before clinical application [18].

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 今年两会热词榜上，"减肥"意外走红。 国家卫健委发出紧急提醒：体重管理刻不容缓，全民健康亮红灯！这绝非推崇"以瘦为美"或制造焦虑，而是基于严峻健康现实。肥胖已成全 球公共卫生危机，是多种代谢疾病的元凶，直接引发2型糖尿病、心血管疾病及众多难言之隐。身边案例不胜枚举：奇点糕的朋友三番五次 医院求诊，查打嗝做完肠胃镜毫无异常，医生建议：减肥；足跟剧痛就诊，医生直言：体重过大压迫所致，减肥是根本。是的，明天就开 始！ 体重管理双管齐下：一方面靠自律，合理运动、规律作息、科学饮食（详见往期文章）；另一方面借助外力，包括药物干预或手术治疗。 目前市场上司美格鲁肽、利拉鲁肽等GLP-1受体激动剂已获减重适应症批准。这类药物本质是模拟人体内天然生物活性肽GLP-1，参与能量 平衡调节、食欲控制与体重管理。 近期重磅消息！美国斯坦福大学Katrin J. Svensson团 ...